Abstract:

This review critically reviews the article monoclonal antibodies therapy in neuro oncology The Brain tumors In applying mAb therapy to brain tumors, both expectations and interpretation are seems difficult due to blood-brain barrier (BBB).It prevents the antibodies from entry into the brain but in case of brain tumors their entry is more complex. Brain tumors (the target), antibodies (the magic), how antibodies attack tumor (the bullet) and how they reach it (through blood brain barrier) are reviewed .With this as introduction, practical experience with mAbs for brain tumor targets is by Clinical experience with mAbs in brain tumor therapy indicates that it is less inherently toxic than the conventional therapies and far safer for widespread delivery

Three of the best-studied antibody/target combinations Bevacizumab and GBM. It hard to define the effect of the antibody itself on tumor growth bevacizumab primarily reduces edema. Other questions concern response criteria. How to weigh overall survival as opposed to progression-free survival; Rituximab and PCNSL Rituximab targets the common B-cell marker CD20 PCNSL, which is typically a B-cell lymphoma. Trastuzumab and metastastic breast cancer Monoclonal antibodies (mAbs) serve as tumor-specific magic bullets in two ways. As bullets, they would move through the blood to reach and attack tumor targets and specificity of a single antibody would provide the magic , breast cancer patients respond to systemic mAb treatment, but then metastases appear in the brain. Limitations of clinical trials and drawbacks of pre-clinical models interpretation of clinical results difficult - increase in overall or progression-free survival, or simply an improved quality of life, are certainly of benefit to brain tumor patients- delivery strategies and tumor sites

References:

[1.] Beduneau, A., Saulnier, P., & Benoit, JP., (2007). Active targeting of brain tumors using nanocarriers. Biomaterials. 28:4947–4967.

[2.] Cheng, X., & Hung, MC., (2007). Breast cancer brain metastases. Cancer Metastasis 26:635–643.

[3.] Choi, YK., & Kim, KW.,(2008). Blood-neural barrier: its diversity and coordinated cell-to-cell communication.

[4.] Deeken, JF.,& Loscher, W., (2007). The blood-brain barrier and cancer: transporters, treatment and Trojan horses.

[5.] Ferreri, AJ., & Reni, M.,( 2007). Primary central nervous system lymphoma. Crit Rev Oncol Hematol.

[6.] Gerstner, ER., & Fine, RL.,( 2007). Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.

[7.] Kim, WY.,& Lee, HY.,( 2009).Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors.

[8.] Neelapu, SS., Kwak, LW., Kobrin, CB., Reynolds, CW., Janik, JE., & Dunleavy, K,, et al.( 2005).Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

[9.] Poulsen, HS., Grunnet, K., Sorensen, M., Olsen, P., Hasselbalch, B., & Nelausen, K,, et al. . (2009). Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

[10.]   Rubenstein, JL., Kim, J., Ozawa, T., Zhang, M., Westphal, M.,& Deen, DF., et al(2000).Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia.

[11.]   Sathornsumetee, S., Rich, & JN.,( 2007).Antiangiogenic therapy in malignant glioma: promise and challenge. Pubmed-NCBI.

[12.]   Saunders, NR., Ek, CJ.,& Habgood, MD.,( 2008). Dziegielewska KM, Barriers in the brain: a renaissance.

[13.]   Strome, SE., Sausville, EA., & Mann, D.,(2007)A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist12:1084–1095.

[14.]   Takahashi, JA., Llena, JF., & Hirano, A.,(1996) Pathology of cerebral metastases. Neurosurg Clin N Am.7:345–367.